Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer

Inclusion Criteria

• Prostate cancer
• Radical prostatectomy or external beam irradiation therapy within 6 months before study entry.
• No bone metastases according to bone scan

Exclusion Criteria

• Metastatic prostate cancer
• Hormone ablation therapy for more than 3 months before/after radical prostatectomy and external beam irradiation therapy
• Treatment with bisphosphonates or other drugs known to affect the skeleton within the past year.

Other protocol-defined inclusion / exclusion criteria may apply.